DRUG PRODUCT DEVELOPMENT SERVICES
Outstanding biopharmaceutical services for all stages of development
Coriolis is the expert partner of choice for biopharmaceutical development! We support our clients from early-stage research and preclinical phase to and beyond market approval by providing the right services for your needs including formulation development, lyophilization process development, forced degradation, stability studies, and product characterization.
Our highly skilled project teams apply cutting-edge technologies tailored to your development phase. With our collaborative approach, we identify the most suitable study design to provide the best chances of success and to ensure your return on investment.
Reach your development goals faster through science-driven and flexible solutions that align with your global strategy.
Early-stage development services for preclinical phases
Get on the right track early, with our tailored services for early R&D stages. Our experienced scientists perform developability and manufacturability assessments to assist in lead candidate selection, conduct preformulation studies to assess critical degradation pathways, develop simple yet robust and flexible formulations for your early-stage product and supply preclinical batches for toxicological studies. During project planning, we account for special project challenges such as limited supply of material, relevant deadlines, need for high-throughput analytical techniques, flexibility towards scope changes, need for readily available methods and procedures.
Clinical and late-stage development services
A robust drug product that is fit for clinical and commercial application: that is the goal of our clinical development and late-stage services. We develop liquid and lyophilized formulations and take application devices and container closure integrity of the primary packaging into account. Our expert scientists perform long-term as well as in-use stability studies and perform troubleshooting activities including the characterization and identification of (sub)visible particles. Modern cGMP facilities enable us the development, qualification, and validation of analytical methods on fully qualified equipment and a subsequent lot release testing with full QA involvement.